United States securities and exchange commission logo





                              August 5, 2020

       Mark P. Lappe
       Chief Executive Officer
       Inhibrx, Inc.
       11025 N. Torrey Pines Road, Suite 200
       La Jolla, CA 92037

                                                        Re: Inhibrx, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed July 28, 2020
                                                            File No. 333-240135

       Dear Mr. Lappe:

              We have reviewed your registration statement and have the
following comment. In our
       comment we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Form S-1 filed July 28, 2020

       Dilution, page 72

   1.                                                   Please tell us why you
did not exclude your right-of-use assets, an intangible asset, from
                                                        your calculation of net
tangible book value.
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.

              Refer to Rules 460 and 461 regarding requests for acceleration.
Please allow adequate
       time for us to review any amendment prior to the requested effective
date of the registration
       statement.
 Mark P. Lappe
Inhibrx, Inc.
August 5, 2020
Page 2

       You may contact Jeanne Bennett at (202) 551-3606 or Kate Tillan at (202)
551-3604 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Laura Crotty at (202) 551-7614 or Mary Beth Breslin at (202) 551-3625
with any other
questions.



                                                          Sincerely,
FirstName LastNameMark P. Lappe
                                                          Division of
Corporation Finance
Comapany NameInhibrx, Inc.
                                                          Office of Life
Sciences
August 5, 2020 Page 2
cc:       Melanie Levy
FirstName LastName